Tuesday, 30 August 2016
Abano Healthcare Group Limited Ordinary Shares
For the purposes of NZX Listing Rule 3.3.5, Abano Healthcare Group Limited
advises that the closing date for director nominations is Monday 12 September
2016. All nominations must be received by 4.00 pm on the closing date.
Nominations may only be made by a shareholder entitled to attend and vote at
the Annual Meeting, and must be accompanied by the consent in writing of the
Nominations should be addressed to:
Abano has provided ongoing disclosure notices for the following Abano
directors and management:
Ted van Arkel
End CA:00287978 For:ABA Type:RELINT Time:2016-08-26 11:25:07 more»
Abano Healthcare Group is presenting to institutional investors in Australia
today. A copy of the presentation is attached.
End CA:00287840 For:ABA Type:ADDRESS Time:2016-08-25 08:32:20 more»
Disclosure of movement of 1% or more in substantial holding
or change in nature of relevant interest, or both
Sections 277 and 278, Financial Markets Conduct Act 2013
Note: This form must be completed in accordance with the instructions at the
end of the form.
To New Zealand Exchange
To Abano Healthcare Group Ltd
Relevant event being disclosed: Movement of 1% or more in the substantial
Date of relevant event: 22 Augu more»
Abano Healthcare Group (NZX:ABA) has today announced the appointment of Dr
Ginni Mansberg as an independent director effective from 24 August 2016.
Dr Mansberg is a Sydney-based GP with a successful clinical practice. She is
a member of the Australian Institute of Company Directors and sits on a
number of corporate and not for profit Advisory Boards, including the
Australian Cervical Cancer Foundation, and the Australian Immunization
NOTICE PURSUANT TO LISTING RULE 7.12.1
22 August 2016
To: NZX Limited
For the purposes of NZX Main Board Listing Rule 7.12.1, Abano Healthcare
Group Limited advises the following in respect of the issue of new ordinary
Listing Rule 7.12.1
(a) Class of Security and ISIN: Fully paid ordinary shares.
(b) Number issued: 194,282 ordinary shares
(c) Nominal value/issue prices: $1,571,7 more»
Abano Healthcare Group Limited (NZX:ABA) advises that the strike price for
shares issued in lieu of the cash 2016 Final Dividend under its Dividend
Reinvestment Plan (DRP) is $8.09 per share.
The issue price has been determined, in accordance with the DRP, as the
volume weighted average sale price for all Abano shares sold on the NZX over
the five trading days immediately following the record date of 11 August
2016, less a 2.5% discount.
Abano Healthcare Group is pleased to present the 2016 Annual Review. This
accompanies the Financial Statements for the year ended 31 May 2016, which
were released on 27 July 2016.
The 2016 Annual Report will be available online at www.abano.co.nz/report.
End CA:00286874 For:ABA Type:ANNREP Time:2016-08-08 13:57:41 more»
Healthcare investor, Abano Healthcare Group (NZX: ABA) has today released its
financial results for the year ended 31 May 2016 reporting a Net Profit After
Tax (NPAT) of $28.4m and a 33% increase in the final dividend to 20 cents per
The full year results include a gain on sale of $20.2m on the $32m sale of
Abano''s 50% shareholding in Bay International Limited. As this ceased to be
recognised as an equity accounted investment from more»
ABANO FULL YEAR RESULTS TO BE RELEASED ON 27 JULY 2016
Abano Healthcare Group (NZX:ABA) intends to announce its results for the
financial year ended 31 May 2016 on Wednesday 27 July 2016, prior to 9am
This will be followed by an analyst and investor conference call at 10.00am
NZST to review the FY16 results and discuss the Company''s outlook for the
2017 financial year.
To attend the conference call, participants will need to d more»